Nevro Corp. (NVRO), announced its preliminary fourth-quarter and full-year 2023 revenue results. The company also announced a restructuring, including laying off 5% of its workforce, that will be substantially complete by the end of the first quarter of 2024.
The vast majority of layoffs affected internally focused employees and not customer-facing personnel in the field.
For the fourth quarter 2023, the company now expects worldwide revenue of about $116.0 million, up 2% as reported and 1% constant currency compared with fourth-quarter 2022.
For the full year 2023, worldwide revenue are expected to be about $425.0 million, representing 5% growth reported and 4.5% on a constant currency basis.
Painful Diabetic Neuropathy indication (PDN) fourth quarter sales are expect eo be about $22.4 million, up 29% over 2022, bringing full-year 2023 PDN sales to $77.9 million and 63% growth over full-year 2022.
Nevro's preliminary, unaudited full-year 2023 worldwide revenue is expected to be approximately $425.0 million, an increase of 5% as reported, or an increase of 4.5% on a constant currency basis, compared with $406.4 million for full-year 2022.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.